Observational study on patients with non-alcoholic fatty liver disease
Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
This study is looking at liver tissue from people with non-alcoholic fatty liver disease to see how certain body signals relate to weight gain and insulin resistance over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Trial ID | NCT00575133 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze liver tissue samples from patients diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) to understand the role of intracellular signaling pathways in relation to adiposity and insulin resistance. Patients will be screened for eligibility, and those who meet the criteria will undergo various assessments, including radiological examinations and potential liver biopsies for histological confirmation. The study will collect baseline data and follow patients annually to monitor disease progression and gather additional serum samples for future analysis.
Who should consider this trial
Good fit: Ideal candidates are individuals with histologically confirmed fatty liver disease.
Not a fit: Patients with significant alcohol consumption, viral hepatitis, autoimmune hepatitis, metabolic diseases, or those on hepatotoxic medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of NAFLD and lead to improved management strategies for patients.
How similar studies have performed: Other studies have explored similar pathways in liver diseases, but this specific approach focusing on NAFLD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients with histologically confirmed fatty liver disease Exclusion criteria: * History of significant alcohol consumption * Viral hepatitis * Autoimmune hepatitis * Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency) * Hepatotoxic medication (e.g. amiodarone).
Where this trial is running
Zurich, Canton of Zurich
- University Hospital Zurich, Endocrinology and Diabetology — Zurich, Canton of Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Giatgen Spinas, Prof. MD — University Hospital Zurich, Endocrinology and Diabetology
- Study coordinator: Oliver Tschopp
- Email: oliver.tschopp@usz.ch
- Phone: +41 (0)44 255 11 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.